Adaptive Biotechnologies预计MRD业务全年营收将达2.55亿至2.65亿美元

美股速递
Feb 06

生物技术公司Adaptive Biotechnologies Corp(ADPT)公布其微小残留病(MRD)业务板块的全年营收指引。该公司预计,该业务在2024财年的总收入将介于2.55亿美元至2.65亿美元之间。这一预测反映了公司对MRD检测市场持续增长及自身商业化执行能力的信心。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10